Effectiveness of immunological agents in non-small cell lung cancer.
NSCLC
adoptive T cell therapy
cancer
cancer vaccines
immunotherapy
monoclonal antibodies
oncolytic viruses
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
08
2022
received:
01
11
2021
accepted:
08
10
2022
pubmed:
27
10
2022
medline:
27
1
2023
entrez:
26
10
2022
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) continues to claim millions of lives worldwide. Although its poor prognosis is largely attributed to the lack of adequate and precise detection technologies, cancer cells' suppression of the immune system adds on to the difficulty of identifying abnormal NSCLC tumors in their early stages. Therefore, cancer immunotherapy, which activates the immune system and helps it fight tumors, has recently become the most sought-after technique, especially in the advanced stages of NSCLC, where surgery or chemotherapy may or may not bring about the desired survival benefits in patients. This review focuses on the various immunotherapeutic interventions and their efficacy in advanced NSCLC clinical trials. Monoclonal antibodies like anti-PD-1/PD-L1 agents and anti-CTLA-4 antibodies, cancer vaccines, oncolytic viruses and adoptive T cell therapy have been discussed in brief. Furthermore, the effects of gender, age, and race on the efficacy of immune checkpoint inhibitors and suggest plausible future approaches in the realm of immuno-oncology. Immunotherapy is used alone or in combination either with other immunological agents or with chemotherapy. However, the efficacy of these strategies depends extensively on various demographic variables, as some patients respond perfectly well to immunotherapy, while others do not benefit at all or experience disease progression. By targeting a "hallmark" of cancer (immune evasion), immunotherapy has transformed NSCLC management, though several barriers prevent its complete effectiveness. All these immunological strategies should be interpreted in the current setting of synergistic treatment, in which these agents can be combined with chemotherapy, radiotherapy, and, or surgery following patient and tumor characteristics to proportionate the best-individualized treatment and achieve superior results. To better pursue this goal, further investigations on cost-effectiveness and sex-gender, race, and age differences in immunotherapy are needed.
Sections du résumé
BACKGROUND AND AIM
Non-small cell lung cancer (NSCLC) continues to claim millions of lives worldwide. Although its poor prognosis is largely attributed to the lack of adequate and precise detection technologies, cancer cells' suppression of the immune system adds on to the difficulty of identifying abnormal NSCLC tumors in their early stages. Therefore, cancer immunotherapy, which activates the immune system and helps it fight tumors, has recently become the most sought-after technique, especially in the advanced stages of NSCLC, where surgery or chemotherapy may or may not bring about the desired survival benefits in patients.
METHODS
This review focuses on the various immunotherapeutic interventions and their efficacy in advanced NSCLC clinical trials. Monoclonal antibodies like anti-PD-1/PD-L1 agents and anti-CTLA-4 antibodies, cancer vaccines, oncolytic viruses and adoptive T cell therapy have been discussed in brief. Furthermore, the effects of gender, age, and race on the efficacy of immune checkpoint inhibitors and suggest plausible future approaches in the realm of immuno-oncology.
RESULTS
Immunotherapy is used alone or in combination either with other immunological agents or with chemotherapy. However, the efficacy of these strategies depends extensively on various demographic variables, as some patients respond perfectly well to immunotherapy, while others do not benefit at all or experience disease progression. By targeting a "hallmark" of cancer (immune evasion), immunotherapy has transformed NSCLC management, though several barriers prevent its complete effectiveness.
CONCLUSIONS
All these immunological strategies should be interpreted in the current setting of synergistic treatment, in which these agents can be combined with chemotherapy, radiotherapy, and, or surgery following patient and tumor characteristics to proportionate the best-individualized treatment and achieve superior results. To better pursue this goal, further investigations on cost-effectiveness and sex-gender, race, and age differences in immunotherapy are needed.
Identifiants
pubmed: 36289059
doi: 10.1002/cnr2.1739
pmc: PMC9981233
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1739Informations de copyright
© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Front Immunol. 2020 Feb 11;11:159
pubmed: 32117295
Ann Oncol. 2020 May;31(5):609-618
pubmed: 32201234
Lung Cancer. 2019 Apr;130:59-66
pubmed: 30885353
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
J Clin Oncol. 2019 Aug 20;37(24):2105-2119
pubmed: 31157579
Onco Targets Ther. 2016 Mar 23;9:1767-76
pubmed: 27042127
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
Am J Public Health. 2017 Feb;107(2):e1-e8
pubmed: 28075632
Clin Transl Oncol. 2019 Jan;21(1):3-17
pubmed: 30446985
JAMA Oncol. 2022 Aug 1;8(8):1097-1098
pubmed: 35679027
Nature. 2019 Mar;567(7749):530-534
pubmed: 30814732
Crit Rev Oncol Hematol. 2020 Sep;153:102948
pubmed: 32645684
Lung Cancer. 2017 Oct;112:200-215
pubmed: 29191596
JAMA Netw Open. 2021 May 3;4(5):e218787
pubmed: 33938936
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075
pubmed: 29385894
Int J Mol Sci. 2017 Feb 10;18(2):
pubmed: 28208579
Ther Adv Med Oncol. 2012 Mar;4(2):43-50
pubmed: 22423263
J Immunother Cancer. 2019 Jan 9;7(1):6
pubmed: 30626434
Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221
pubmed: 32474768
J Thorac Dis. 2014 May;6 Suppl 2:S217-23
pubmed: 24868439
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
Front Oncol. 2021 Jun 15;11:639745
pubmed: 34211836
Aging (Albany NY). 2021 Jun 4;13(11):15413-15432
pubmed: 34086601
Front Oncol. 2020 Feb 18;10:137
pubmed: 32133288
Mol Ther. 2021 Feb 3;29(2):658-670
pubmed: 33160076
Biomed Res Int. 2019 May 13;2019:9853701
pubmed: 31214620
Immunooncol Technol. 2019 Oct 09;3:1-7
pubmed: 35757302
Br J Cancer. 2004 Aug 31;91(5):817-21
pubmed: 15266309
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100
pubmed: 29346180
Front Med (Lausanne). 2015 Nov 27;2:84
pubmed: 26640780
Cancer. 2020 Dec 1;126(23):5040-5049
pubmed: 32902858
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Chest. 2003 Jan;123(1 Suppl):221S-225S
pubmed: 12527581
Cancer Med. 2016 Sep;5(9):2567-78
pubmed: 27416962
Front Immunol. 2019 Jul 19;10:1719
pubmed: 31379886
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Cancer Med. 2019 Jul;8(8):4023-4031
pubmed: 31165589
Sci China Life Sci. 2016 May;59(5):468-79
pubmed: 26968708
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Biomedicines. 2020 Jul 21;8(7):
pubmed: 32708265
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
J Comp Eff Res. 2020 Apr;9(5):327-340
pubmed: 32056442
Biomedicines. 2017 Jan 04;5(1):
pubmed: 28536345
Sci Rep. 2020 Aug 12;10(1):13662
pubmed: 32788651
Immunotherapy. 2020 Jun;12(8):587-603
pubmed: 32378444
J Thorac Dis. 2018 May;10(Suppl 13):S1602-S1614
pubmed: 29951309
Cancer Rep (Hoboken). 2023 Jan;6(1):e1739
pubmed: 36289059
Front Immunol. 2017 Mar 13;8:269
pubmed: 28348561
Int Immunopharmacol. 2016 May;34:244-249
pubmed: 26994448
Ann Surg Oncol. 2022 Dec;29(13):7958-7960
pubmed: 35999415
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Mol Cancer. 2020 Sep 11;19(1):141
pubmed: 32917214
J Clin Med. 2018 Dec 12;7(12):
pubmed: 30545122
Transl Lung Cancer Res. 2020 Aug;9(4):1124-1137
pubmed: 32953491
J Med Life. 2016 Jul-Sep;9(3):240-248
pubmed: 27974927
J Clin Oncol. 2017 Oct 20;35(30):3449-3457
pubmed: 28854067
Lung Cancer. 2017 Apr;106:102-109
pubmed: 28285683
Front Immunol. 2019 Feb 04;10:108
pubmed: 30778352
JAMA Oncol. 2020 May 1;6(5):661-674
pubmed: 32271377
J Hematol Oncol. 2020 May 24;13(1):58
pubmed: 32448366
Thorac Cancer. 2021 May;12(10):1617-1619
pubmed: 33760389
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135
pubmed: 28503645
Target Oncol. 2019 Dec;14(6):759-768
pubmed: 31728860
Mol Diagn Ther. 2017 Feb;21(1):85-93
pubmed: 27667773
Transl Lung Cancer Res. 2015 Apr;4(2):177-90
pubmed: 25870800
Cancers (Basel). 2021 Mar 18;13(6):
pubmed: 33803762
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Lancet Oncol. 2011 Nov;12(12):1125-33
pubmed: 22019520
Thorac Cancer. 2020 Sep;11(9):2552-2560
pubmed: 32705787
Front Immunol. 2021 Feb 12;11:620374
pubmed: 33679709
J Clin Oncol. 2022 Apr 20;40(12):1356-1384
pubmed: 34936470
Acta Oncol. 2020 Mar;59(3):247-248
pubmed: 32036733
Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91
pubmed: 29098404
Cancer. 2020 Jan 15;126(2):260-270
pubmed: 31691957
J Clin Med Res. 2019 Apr;11(4):225-236
pubmed: 30937112
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Expert Opin Biol Ther. 2018 Jul;18(7):829-835
pubmed: 29936901
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Adolesc Young Adult Oncol. 2019 Oct;8(5):525-528
pubmed: 31199707
Future Oncol. 2018 Apr;14(10):907-917
pubmed: 29260582
Methods Mol Biol. 2017;1641:115-128
pubmed: 28748460
Drugs Context. 2019 Jun 17;8:212578
pubmed: 31258616
Ann Transl Med. 2016 May;4(10):201
pubmed: 27294097
J Thorac Dis. 2020 Aug;12(8):4516-4521
pubmed: 32944366
Front Immunol. 2020 Nov 26;11:572172
pubmed: 33324397
Life Sci. 2019 Sep 15;233:116713
pubmed: 31386875
Future Oncol. 2019 Nov;15(31):3633-3646
pubmed: 31650854
J Thorac Oncol. 2020 Aug;15(8):1351-1360
pubmed: 32302702
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20
pubmed: 29299404
Ther Adv Med Oncol. 2018 Oct 11;10:1758835918804151
pubmed: 30344651
BMC Immunol. 2018 Apr 16;19(1):14
pubmed: 29661145
Indian J Med Paediatr Oncol. 2013 Apr;34(2):121-5
pubmed: 24049303
J Clin Oncol. 2016 Sep 10;34(26):3204-12
pubmed: 27432922
J Cancer. 2020 Mar 5;11(11):3407-3415
pubmed: 32231747
J Thorac Dis. 2020 Jul;12(7):3796-3803
pubmed: 32802459
Cancer Immun. 2013;13:5
pubmed: 23390376
Cancer Immunol Immunother. 2021 May;70(5):1177-1188
pubmed: 33113004
J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101
pubmed: 30775032
J Natl Cancer Inst. 2019 Aug 1;111(8):772-781
pubmed: 31106827
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
World J Clin Oncol. 2021 Feb 24;12(2):103-114
pubmed: 33680877